60
603087.SHG Gan & Lee Pharmaceuticals Co Ltd
- Market cap
- CNY 43.2B
- P/E
- 36.2x
- P/B
- 3.45x
- ROE
- 9.6%
- Dividend yield
- 1.38%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603087.SHG undervalued?
Graham number603087.SHG trades 135.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gan & Lee Pharmaceuticals Co Ltd fundamental analysis
No fundamental analysis for Gan & Lee Pharmaceuticals Co Ltd yet.
Gan & Lee Pharmaceuticals Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also…
Full company profileGan & Lee Pharmaceuticals Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gan & Lee Pharmaceuticals Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.77B | 2.37B | 2.39B | 2.90B | 3.36B | 3.61B | 1.71B | 2.61B | 3.05B | 4.05B | 4.49B |
| Gross Profit | 1.61B | 2.16B | 2.20B | 2.66B | 3.05B | 3.21B | 1.27B | 1.88B | 2.27B | 3.07B | 3.36B |
| Operating Income | 900M | 1.27B | 1.11B | 1.40B | 1.45B | 1.70B | -569M | 315M | 632M | 794M | 1.21B |
| EBITDA | 888M | 1.30B | 1.18B | 1.44B | 1.57B | 1.57B | -480M | 401M | 546M | 1.53B | 1.21B |
| Net Income | 770M | 1.08B | 934M | 1.17B | 1.23B | 1.45B | -440M | 340M | 615M | 1.14B | 1.14B |
| EPS | 1.51 | 2.14 | 1.85 | 2.08 | 2.19 | 2.59 | -0.78 | 0.60 | 1.04 | 1.91 | 1.92 |
| Balance Sheet | |||||||||||
| Total Assets | 2.60B | 3.74B | 4.69B | 6.03B | 9.51B | 10.9B | 10.6B | 11.7B | 12.0B | 12.6B | 13.7B |
| Total Liabilities | 348M | 408M | 424M | 556M | 569M | 686M | 1.02B | 973M | 988M | 999M | 1.70B |
| Shareholders' Equity | 2.26B | 3.34B | 4.27B | 5.47B | 8.94B | 10.2B | 9.59B | 10.7B | 11.1B | 11.6B | 12.0B |
| Cash & Short-term Investments | 535M | 817M | 594M | 1.54B | 3.61B | 4.93B | 4.53B | 4.85B | 2.40B | 2.09B | 1.73B |
| Total Debt | 34.6M | 27.1M | 35.9M | 38.4M | 9.09M | 20.1M | 15.9M | 5.45M | 3.31M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 770M | 950M | 418M | 1.15B | 1.24B | 1.08B | 297M | 428M | 537M | 784M | - |
| Capital Expenditure | 258M | 431M | 513M | 407M | 582M | 692M | 983M | 553M | 441M | 926M | 1.38B |
| Free Cash Flow | 511M | 519M | -95.4M | 747M | 659M | 386M | -687M | -444M | 96.5M | -142M | -492M |
| Ratios | |||||||||||
| ROE | 34.1% | 32.4% | 21.9% | 21.3% | 13.8% | 14.3% | -4.6% | 3.2% | 5.6% | 9.8% | 9.6% |
| ROA | 29.6% | 28.9% | 19.9% | 19.4% | 12.9% | 13.4% | -4.1% | 2.9% | 5.1% | 9.1% | 8.4% |
| Net Profit Margin | 43.4% | 45.6% | 39.1% | 40.3% | 36.6% | 40.2% | -25.7% | 13.0% | 20.2% | 28.2% | 25.5% |
| Debt to Equity | 0.02x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Gan & Lee Pharmaceuticals Co Ltd dividends
- Dividend yield
- 1.38%
- Forward dividend
- 1.00 CNY
- Payout ratio
- 52.3%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 598M | 1.00 | 52.3% |
| 2024 | CNY 421M | 0.71 | 68.4% |
| 2023 | - | - | - |
| 2022 | CNY 168M | 0.30 | - |
| 2021 | CNY 225M | 0.40 | 15.5% |
| 2020 | CNY 201M | 0.36 | 16.3% |
| 2019 | CNY 201M | 0.36 | 17.2% |
| 2018 | CNY 201M | 0.40 | 21.5% |
| 2017 | CNY 1.73M | 0.00 | 0.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Aug 20, 2020.
Who owns Gan & Lee Pharmaceuticals Co Ltd
- Insiders 42.06%
- Institutions 11.23%
- Public & others 46.71%
- Shares outstanding 597M
- Free float 337M
Gan & Lee Pharmaceuticals Co Ltd company profile
- Company name
- Gan & Lee Pharmaceuticals Co Ltd
- Ticker
- 603087.SHG
- ISIN
- CNE100003ZH1
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5,309
- Fiscal year end
- December
- Address
- No. 8, Nanfeng West 1st Street, Beijing, China, 101109
- Phone
- 86 10 5696 5000
- Website
- ganlee.com
About Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insulin pen needle. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
Gan & Lee Pharmaceuticals Co Ltd management
10- Mr. Wei ChenChairman & GM · born 1980
- Mr. Weiqiang SongDeputy GM & Director · born 1982
- Mr. Kai DuDeputy GM & Director · born 1977
- Ms. Rong ZouDeputy GM & Secretary · born 1983
- Ms. Zifei YuanDeputy General Manager · born 1989
- Mr. Zhi LiDeputy General Manager · born 1993
- Mr. Qianming Wang Ph.D.CFO & Deputy GM
- Li ZhouHead of Accounting
- Ms. Yajuan FengHead of Administrative Department · born 1992
- Dr. Ting JiaChief Medical Officer